BGI didn’t infringe one Illumina patent, fails to invalidate another

The US District Court for the Northern District of California has denied an attempt by Chinese company BGI Genomics to invalidate an Illumina DNA sequencing patent in a summary judgment, leaving the dispute over infringement of another Illumina patent to be decided at trial.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Medtech

Could everyday hospital equipment be the next defence against counterfeit medicines?

23 February 2026 A new study suggests the equipment already found in hospitals worldwide could offer a front line against fake vaccines and insulin.

Medtech

Danaher moves to acquire Masimo in $9.9bn deal

18 February 2026 The science and technology conglomerate’s big diagnostics bet comes with monitoring technology, an AI-powered product pipeline, and a litigation history that has kept Silicon Valley’s biggest player on the back foot.

Medtech

Chinese invisible braces maker hits back at infringement claims

22 August 2025 The company has dismissed recent patent infringement claims from the Invisalign maker as “frivolous and entirely without merit,” pledging a vigorous defence.

More features

LSPN Awards 2026 finalists revealed

Natera and a rival draw the line under five-year fight

SCOTUS flooded with briefs calling for reversal of ‘skinny label’ ruling

Eli Lilly escapes $278m payout in biotech licensing dispute

Novo battles for GLP-1 leadership with fresh lawsuit and slashed prices

Wiggin’s new litigation partner deepens ‘technically complex’ offer

Could everyday hospital equipment be the next defence against counterfeit medicines?

BioNTech fires shots at Moderna's next-generation vaccine

BGI didn’t infringe one Illumina patent, fails to invalidate another

More on this story

Editor's picks

Editor's picks

More features